Related Experiment Videos

Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes

J W Evans1, K Yudoh, Y M Delahoussaye

  • 1Department of Radiation Oncology, Stanford University School of Medicine, California 94305, USA.

Cancer Research
|May 30, 1998
PubMed

Insights

Tirapazamine (TPZ) drug activity in cancer cells stems from DNA damage caused by radicals generated within the nucleus. Cytoplasmic metabolism of TPZ is likely irrelevant to its therapeutic effect on hypoxic cells.

Area of Science:

  • Pharmacology
  • Cancer Biology
  • Molecular Toxicology

Background:

  • Tirapazamine (TPZ) is an anticancer drug with selective cytotoxicity for hypoxic tumor cells.
  • Its mechanism involves DNA damage induced by free radicals generated from TPZ.
  • The specific enzymes responsible for TPZ reduction remain unidentified.

Purpose of the Study:

  • To investigate the cellular location of TPZ metabolism and DNA damage induction.
  • To determine the contribution of nuclear versus cytoplasmic TPZ metabolism to cytotoxicity.

Main Methods:

  • TPZ metabolism and DNA damage were measured in A549 human lung cancer cells and isolated nuclei.
  • Enzymatic reduction and radical formation of TPZ were assessed in both whole cells and nuclear fractions.

Main Results:

  • Intranuclear TPZ metabolism accounted for significant DNA damage, despite lower metabolic rates compared to whole cells.
  • Extranuclear TPZ radicals did not contribute to DNA damage within the nucleus.
  • Approximately 80% of TPZ metabolism occurring in the cytoplasm was found to be irrelevant to DNA damage.

Conclusions:

  • TPZ-induced DNA damage and cytotoxicity are primarily mediated by radicals generated within the cell nucleus.
  • Cytoplasmic metabolism of TPZ is likely not essential for its anticancer activity against hypoxic cells.

Related Concept Videos